Knowledge of and opinions on HIV preexposure prophylaxis among front-line service providers at Canadian AIDS service organizations.

Abstract

Oral daily tenofovir/emtricitabine (Truvada) is approved in the United States for HIV preexposure prophylaxis (PrEP) but has generated controversy in the media and within HIV-affected communities. We conducted an online survey about PrEP-related knowledge, experience, opinions, and learning needs, and received 160 responses from service providers at… (More)
DOI: 10.1089/AID.2013.0090

Topics

4 Figures and Tables